Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea

Asan Medical Center1,000 enrolled

Overview

The aim of this study is to examine the prevalence of the Metabolic syndrome(MetS) in Korean patients with schizophrenia. Primary objective: • To investigate the prevalence of the MetS in Korean patients with schizophrenia Secondary objectives: • To compare the prevalence of the MetS among 3 groups according to antipsychotics: typical antipsychotic monotherapy group, atypical antipsychotic monotherapy group, 2 or more antipsychotics group (polypharmacy)

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Schizophrenia Metabolic Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of schizophrenia according to DSM-IV-TR * Age between 18-65 years

Locations (1)

Asan medical center

Seoul, South Korea

Outcomes

Primary Outcomes

prevalence of metabolic syndrome (MetS)

MetS will be diagnosed according to NCEP ATP III with the Asian-Pacific abdominal obesity criterion (≥90 cm in men, ≥85 cm in women) 3 or more of the following criteria 1. fasting plasma glucose \>= 100 mg/dl or drug use to treat elevated glucose 2. serum triglyceride (TG) \>= 150 mg/dl or drug use to treat elevated TG 3. HDL cholesterol level \< 40mg /dl in males, \< 50 mg/dl in female or drug use to treat low HDL 4. Systolic BP \>=130 mmHg, diastolic BP \>=85 or drug use to treat hypertension 5. Abdominal obesity : above described

Central Contacts

Yeon-Ho Joo, Ph.D.

CONTACT

82-2-3010-3412 jooyh@amc.seoul.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.